FORT LAUDERDALE, Fla., Nov. 7 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. announced today that Steven Ponder, Ph.D., IDSI Director, Advanced Development, has been invited to join Florida International University (FIU)'s Biomedical Engineering Partnership Program (BMEPP) Advisory Board. Ponder will represent IDSI on the board, which integrates academia, clinical medicine, and the biomedical industry.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
“We are very pleased to have Imaging Diagnostic Systems and Steven Ponder as part of the Advisory Board,” stated Ofer Amit, Biomedical Engineering Partnership Program Director. “The work that IDSI is doing with laser molecular imaging and CT technology places them among the biomedical engineering leaders in South Florida and the nation that comprise our program.”
The advisory board serves as a liaison between FIU’s Department of Biomedical Engineering, biomedical corporations, and the clinical community, providing a forum for the exchange of knowledge, networking, and establishment of joint projects. The Biomedical Engineering Advisory Board is comprised of representatives from prominent hospitals, research centers, and biomedical industry leaders such as Mount Sinai, Cordis, Bioheart, Boston Scientific, and Beckman-Coulter.
“We are pleased to have this opportunity to cooperate with the local academic community and to support the education of the next generation of biomedical engineers,” Ponder stated. “I look forward to a fruitful collaboration between Imaging Diagnostic Systems and Florida International University.”
The next meeting of the Advisory Board will be held on November 23rd.
The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: http://www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Rick Lutz, Imaging Diagnostic Systems, +1-404-261-1196, orlcgroup@mindspring.com
Web site: http://www.imds.com/
